Claims
- 1. An isolated polypeptide comprising:
a) the amino acid sequence of SEQ ID NO: 8; b) the amino acid sequence of SEQ ID NO: 6, or c) the amino acid sequence of SEQ ID NO: 2.
- 2. An antigenic polypeptide comprising:
a) an immunogenic amino acid sequence exhibiting identity overall length of at least 12 amino acids to SEQ ID NO: 8; b) an immunogenic amino acid sequence exhibiting identity over a length of at least 12 amino acids to SEQ ID NO: 6; or c) an immunogenic amino acid sequence exhibiting identity over a length of at least 12 amino acids to SEQ ID NO: 2.
- 3. An antigenic polypeptide of:
a) claim 2a, further comprising:
i) a second length of identity of 12 amino acids; ii) a detection or purification tag; iii) a sequence of another chemokine receptor; or iv) a carbohydrate; b) claim 2b, further comprising:
i) a second length of identity of 12 amino acids; ii) a detection or purification tag; iii) a sequence of another chemokine receptor; or iv) a carbohydrate; or c) claim 2c, further comprising:
i) a second length of identity of 12 amino acids; ii) a detection or purification tag; iii) a sequence of another chemokine; or iv) a carbohydrate.
- 4. The polypeptide of claim 1, which;
a) has a molecular weight of at least 3 kD with natural glycosylation; b) is a synthetic polypeptide; c) is attached to a solid substrate; d) is conjugated to another chemical moiety; e) is a 5-fold or less substitution from natural sequence; or f) is a deletion or insertion variant from a natural sequence.
- 5. A composition comprising:
a) a sterile polypeptide of claim 1a, b) a sterile polypeptide of claim 1b; or c) a sterile polypeptide of claim 1c.
- 6. A kit comprising a polypeptide of claim 1, and:
a) a compartment comprising said polypeptide; and/or b) instructions for use or disposal of reagents in said kit.
- 7. A method of using said polypeptide of claim 1 to:
a) produce an antiserum, comprising immunizing an animal with said polypeptide, and isolating said antiserum; or b) produce an antibody:antigen complex, comprising contacting said polypeptide with a specific antibody, thereby producing said complex.
- 8. A binding compound comprising an antigen binding portion from an antibody, which specifically binds to a polypeptide of claim 1, wherein:
a) said binding compound is an Fv, Fab, or Fab2 fragment; b) said binding compound is conjugated to another chemical moiety; or c) said antibody:
i) is raised against a peptide sequence of a mature polypeptide of FIG. 1 or FIGS. 3A-3C; ii) is raised against a peptide sequence of a mature rodent polypeptide of FIG. 5; iii) is immunoselected; iv) is a polyclonal antibody; v) binds to a denatured rodent CXC N4, rodent DNAXCCR10, or primate BLRx; vi) exhibits a Kd to antigen of at least 30 μM; vii) is attached to a solid substrate, including a bead or plastic membrane; viii) is in a sterile composition; or ix) is detectably labeled, including a radioactive or fluorescent label.
- 9. A kit comprising said binding compound of claim 8, and:
a) a compartment comprising said binding compound; and/or b) instructions for use or disposal of reagents in said kit.
- 10. A composition comprising:
a) a sterile binding compound of claim 8; or b) said binding compound of claim 8 and a carrier, wherein said carrier is:
i) an aqueous compound, including water, saline, and/or buffer; and/or ii) formulated for oral, rectal, nasal, topical, or parenteral administration.
- 11. An isolated or recombinant nucleic acid encoding a polypeptide of claim 1, wherein said nucleic acid:
a) encodes an antigenic peptide sequence of FIG. 1 or FIGS. 3A-3C; b) encodes an antigenic rodent peptide sequence of FIG. 5; c) encodes a plurality of antigenic peptide sequences of Figure or FIGS. 3A-3C; d) encodes a plurality of antigenic peptide sequences of FIGS. 2A-2B; e) exhibits identity of at least 27 nucleotides of SEQ ID NO: 7, 5, or 1; f) is an expression vector; g) further comprises an origin of replication; h) is from a natural source; i) comprises a detectable label; j) comprises synthetic nucleotide sequence; k) is less than 6 kb, preferably less than 3 kb; l) is from a mammal, including a rodent; m) comprises a natural full length coding sequence; n) is a hybridization probe for a gene encoding said protein; or o) is a PCR primer, PCR product, or mutagenesis primer.
- 12. A cell or tissue comprising a recombinant nucleic acid of claim 11.
- 13. The cell of claim 12, wherein said cell is:
a) a prokaryotic cell; b) a eukaryotic cell; c) a bacterial cell; d) a yeast cell; e) an insect cell; f) a mammalian cell; g) a mouse cell; h) a primate cell; or i) a human cell.
- 14. A kit comprising said nucleic acid of claim 11, and:
a) a compartment comprising said nucleic acid; b) a compartment further comprising a polypeptide of SEQ ID NO: 8, 6, or 2; and/or c) instructions for use or disposal of reagents in said kit.
- 15. A nucleic acid which:
a) hybridizes under wash conditions of 45° C. and less than 700 mM salt to SEQ ID NO: 1; b) hybridizes under wash conditions of 45° C. and less than 700 mM salt to SEQ ID NO: 5; c) hybridizes under wash conditions of 45° C. and less than 700 mM salt to SEQ ID NO: 7; d) exhibits identity over a stretch of 30 nucleotides to SEQ ID NO: 7; e) exhibits identity over at least 30 nucleotides to SEQ ID NO: 5; or f) exhibits identity over at least 30 nucleotides to SEQ ID NO 1.
- 16. The nucleic acid of claim 15, wherein:
a) said wash conditions are at 55° C. and/or 500 mM salt; or b) said identity is over at least 55 nucleotides.
- 17. The nucleic acid of claim 16, wherein:
a) said wash conditions are at 65° C. and/or 150 mM salt; or b) said identity is over at least 75 nucleotides.
- 18. A kit comprising said nucleic acid of claim 15, and:
a) a compartment comprising said nucleic acid; b) a compartment further comprising a polypeptide of SEQ ID NO: 8, 6, or 2; and/or c) instructions for use or disposal of reagents in said kit.
- 19. A method of using said nucleic acid of claim 15:a) to produce a duplex nucleic acid, comprising contacting one strand of the nucleic acid to the complementary strand, thereby producing said duplex; or b) to produce a polypeptide, comprising expressing said nucleic acid in a host cell, thereby producing said polypeptide.
- 20. A method of screening for a compound which binds to a polypeptide of claim 1 having SEQ ID NO: 8, comprising contacting said compound to said polypeptide, and detecting binding.
- 21. An isolated polypeptide, comprising the amino acid sequence of SEQ ID NO:8, or a polypeptide having at least about 80% sequence homology thereto.
- 22. An isolated polynucleotide encoding the polypeptide of claim 21.
- 23. The polynucleotide of claim 22, wherein the polynucleotide comprises the nucleotide sequence of SEQ ID NO:7, or a polynucleotide having at least about 80% sequence homology thereto.
- 24. A recombinant vector comprising
(a) a polynucleotide according to claim 22; and (b) control elements that are operably linked to said polynucleotide whereby a coding sequence within said polynucleotide can be transcribed and translated in a host cell, and at least one of said control elements is heterologous to said coding sequence.
- 25. A host cell transformed with the recombinant vector of claim 24.
- 26. A method of producing a recombinant polypeptide comprising:
(a) providing a population of host cells according to claim 25; and (b) culturing said population of cells under conditions whereby a polypeptide encoded by the coding sequence present in said recombinant vector is expressed.
- 27. A method of expressing a recombinant polypeptide comprising:
(a) transforming a host cell with the recombinant vector of claim 22; and (b) causing expression of a polypeptide encoded by the coding sequence present in said recombinant vector.
- 28. The method of claim 27, wherein the host cell is transformed in vivo.
- 29. The method of claim 28, wherein the host cell is in the region of a wound.
- 30. A method of treating a wound comprising:
(a) transforming a host cell in vivo with the polynucleotide of claim 22, wherein the host cell is in the region of a wound; and (b) causing expression of a polypeptide encoded by the coding sequence present in said recombinant vector.
- 31. A method of treating a wound comprising modulating the in vivo expression of an endogenous polynucleotide in the region of the wound, wherein the polynucleotide encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:8.
- 32. The method of claim 31, wherein expression is up-regulated.
- 33. An antibody reactive with the polypeptide of claim 21.
- 34. The antibody of claim 33, wherein the antibody is a polyclonal antibody.
- 35. The antibody of claim 33, wherein the antibody is a monoclonal antibody.
- 36. A method of treating a wound comprising administering the antibody of claim 33 to a subject in need thereof.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. application Ser. No. 09/122,585, filed Jul. 24, 1998, from which priority is claimed pursuant to 35 USC §120, which application is related to U.S. Provisional Application Serial No. 60/053,693, filed Jul. 25, 1997, from which priority is claimed pursuant to 35 USC §119(e)(1), which applications are incorporated herein by reference in their entireties.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60053693 |
Jul 1997 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09122585 |
Jul 1998 |
US |
Child |
09910695 |
Jul 2001 |
US |